Abstract
In the past decade, many adjuvant chemotherapy trials in operable breast cancer have been conducted. The results of these trials have answered a number of questions, but have also raised new issues. Among other issues, results have suggested that relapse-free survival was dependent on the dose of cytotoxic drugs and the timing of initiation of chemotherapy [1, 2]. Routine postoperative irradiation was shown to have a detrimental effect on the efficacy of adjuvant chemotherapy [2, 3]. At M.D. Anderson Hospital, since 1974, a combination of fluorouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC) has been utilized following regional therapy in patients with operable breast cancer. In this paper the dose of cytotoxic drugs, timing of initiation of chemotherapy, and the role of routine postoperative irradiation are evaluated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy of breast cancer. Cancer 44: 793–798
Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
Nissen-Meyer R, Kjellgren K Malmio K et al. (1978) Surgical adjuvant chemotherapy results with one short course with cyclophosphamide alter mastectomy for breast cancer. Cancer 41: 2008–2098
Buzdar A, Smith T, Blumenschein G, Hortobagyi G, Hersh E, Gehan E (1981) Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5-year results. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 419–426
Buzdar A. Blumenschein G, Smith T et al. (1984) Adjuvant chemotherapy with fluorouracil, doxorubicin, and cylophosphamide, with our without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 53: 384–389
Buzdar A, Gutterman J, Blumenschein G et al. (1978) Intensive postoperative chemoimmunotherapy for patients with operable breast cancer. Cancer 41: 1064–1075
Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–225
Breslow N (1970) A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 57: 579–594
Buzdar A, Smith T, Powell K et al. (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Cancer Res Treat 2: 163–169
Buzdar A, Smith T, Blumenschein G et al. (1984) Adjuvant therapy for stage II or III breast cancer M.D. Anderson Hospital experience. In: Blumenschein GR, Montague E (eds) Current controversy in breast cancer. Proceedings of the 26th annual clinical conference, New York, pp 171–184
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Buzdar, A.U., Smith, T.L., Marcus, C.E., Hortobagyi, G.N., Blumenschein, G.R. (1984). Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer. In: Senn, HJ. (eds) Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82357-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-82357-2_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82359-6
Online ISBN: 978-3-642-82357-2
eBook Packages: Springer Book Archive